Research Topics
| Jasper van der LugtSummaryAffiliation: The HIV Netherlands Australia Thailand Research Collaboration Country: Thailand Publications
| Collaborators
|
Detail Information
Publications
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adultsJasper van der Lugt
HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, 104 Ratchadamri Road, Pathumwan, Bangkok 10330, Thailand
J Antimicrob Chemother 61:1145-53. 2008..To study the pharmacokinetics and short-term efficacy of low and standard dose lopinavir/ritonavir and saquinavir combinations in Thai, human immunodeficiency virus (HIV)-infected, treatment-naive patients...- Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individualsJasper van der Lugt
The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
AIDS 23:1176-9. 2009..The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered... 
The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant womenJasper van der Lugt
The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
Antivir Ther 14:443-50. 2009..Pregnancy affects the pharmacokinetics of most protease inhibitors. Saquinavir, when administered in a tablet formulation, has not been studied extensively in this setting...- Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individualsJasper van der Lugt
The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, Bangkok, Thailand
Antivir Ther 14:1001-4. 2009..However quality and safety remains an issue of concern. Therefore, we evaluated minimal plasma concentrations and short-term safety of a generic lopinavir/ritonavir 200/50 mg tablet formulation... - Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected childrenThanyawee Puthanakit
HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
J Antimicrob Chemother 64:1080-6. 2009..Several studies have shown higher plasma concentrations of antiretroviral agents in Thai adults than in Caucasians, suggesting that lower doses may be used... - Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancyReshmie A Ramautarsing
The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
AIDS 25:1299-303. 2011..To investigate whether Thai HIV-1-infected pregnant women require a dose increase of lopinavir/ritonavir (LPV/r) and to assess the safety and efficacy of the generic tablets during pregnancy... - Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice dailyReshmie A Ramautarsing
The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
J Acquir Immune Defic Syndr 59:55-8. 2012..All patients remained virologically suppressed at week 12. In conclusion, LPV/r 200/50mg BID does not lead to adequate lopinavir plasma concentrations. Generic and branded LPV/r have comparable PK-parameters... - Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeksTorsak Bunupuradah
The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
Antivir Ther 14:241-8. 2009.... - Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot studyAnchalee Avihingsanon
HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Pathumwan, Bangkok, Thailand
AIDS Res Hum Retroviruses 28:1170-6. 2012..Despite good virological outcome in our cohort, prolonged exposure to subtherapeutic indinavir concentrations may lead to treatment failure...